Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Leti and Akrivis Develop Nanomedicine Platform for High Payload Targeted Drug Delivery

Published: Saturday, June 21, 2014
Last Updated: Friday, June 20, 2014
Bookmark and Share
New theranostic platform will combine ultrasensitive detection, high payloads and more efficient cell targeting.

CEA-Leti and Akrivis Technologies, LLC have announced their collaboration to develop an extremely adaptable, efficient and highly targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells.

The new platform will be based on Akrivis Technologies’ proprietary Z–TECT™ technology that targets and detects unusually low levels of proteins and molecular targets and Leti’s Lipidot® nanovector delivery capability.

Developed by Akrivis Technologies, LLC, a biopharmaceutical company based in Cambridge, Mass. USA, Z–TECT™ is a unique technology platform that combines nanotechnology, molecular detection and immunology to provide high sensitivity and detection levels across multiple immunoassays and other assay formats, from colorimetric to fluorescent detection in vitro and imaging in vivo.

Developed by Leti and introduced for commercial uses in 2011, the Lipidot® technology is a versatile nano-delivery platform based on very small droplets of oil that encapsulate and carry drugs, fluorescent imaging agents or any other lipophilic payload to targeted cells for diagnosis or treatment.

By combining their delivery and targeting platforms, Leti and Akrivis intend to develop a new, more efficient and safer platform to deliver high payloads specifically to targeted cells. The resulting targeted nanoparticles will be optimized in a first phase for research and pre-clinical in vitro and in vivo applications. Then, in a second phase, they will be further developed clinically for in vitro diagnostics, in vivo imaging and targeted therapy.

“The new targeted nanoparticles jointly developed by Leti and Akrivis Technologies will dramatically improve the effectiveness of both diagnosis and treatment of diseases and reduce dangerous or unpleasant side effects,” said Patrick Boisseau, head of Leti’s nanomedicine program and chairman of the European Technology Platform – Nanomedicine (ETPN). “While specifically designed to meet the needs of pharmaceutical and biotech companies, the new platform will be customizable for other end-user applications such as diagnostics and theranostics.”

“Detecting disease earlier and delivering the precise drug dosage at the right place at the right moment are major steps towards improving patient diagnosis and treatment as well as controlling healthcare costs,” said Joel Berniac, CEO of Akrivis Technologies. “Akrivis and Leti have highly complementary nanomed technology platforms that will come together and offer physicians powerful new options for diagnosis and treatment.”

Supported by AEPI, the Grenoble-Isère economic development agency, Akrivis Technologies and Leti created a joint lab, which was launched on June 2.

“Leti’s collaboration with Akrivis Technologies underscores Grenoble’s strengths as a center for nanomedicine R&D and we are very pleased that they chose Leti and Grenoble for this exciting research and development project,” said Joëlle Seux, AEPI director.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Leti and Diabeloop Project Aims at Developing Artificial Pancreas
Artificial pancreas will automatically deliver the appropriate dose of insulin to patients.
Saturday, July 25, 2015
Leti Announces Launch of First European Nanomedicine Characterization Laboratory
Project combines expertise of 9 partners in 8 countries to foster nanomedicine innovation and facilitate regulatory approval.
Tuesday, July 07, 2015
Eveon, Leti Mark Milestone in Fabrication of Smart Bolus-type Micro-pump
Both Companies announces the demonstration of liquid-pumping for smart drug delivery.
Friday, March 14, 2014
Leti Announces Project to Develop New Fingerprint Technology
Ultra-high resolution sensing uses vertical piezoelectric nanowire matrices to reconstruct the smallest features of human fingerprints.
Tuesday, February 18, 2014
PIEZOMAT Project Targets New Fingerprint Technology
Ultra-high resolution sensing uses vertical piezoelectric nanowire matrices to reconstruct the smallest features of human fingerprints.
Thursday, February 13, 2014
Leti Announces MEMS Research Collaboration with OMRON
Leti’s first collaboration with a Japanese MEMS producer.
Monday, December 09, 2013
CEA-Leti Signs Agreement with Qualcomm
Agreement to assess Leti’s sequential 3D technology.
Monday, December 09, 2013
Alim-Louis Benabid Honored by U.S. Research Institute
Benabid has received the Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research.
Friday, October 11, 2013
CEA-Leti Announces €1 Million Funding
bpifrance (ex OSEO) awarded grant to speed preclinical development of cancer-detecting nanoparticles.
Thursday, July 04, 2013
Patrick Boisseau Elected Chairman of the ETPN
Program will focus on building a structure that speeds innovations’ time to market and patients, while keeping Europe’s nanomed IP at home.
Monday, March 25, 2013
Attolight and Leti Launch Joint-Development Program
Program to extend applications for Company’s cathodoluminescence technology.
Monday, October 29, 2012
CEA-Leti and 7 Partners to Study Ways to Improve Treatment of Inflammatory Bowel Disease
Goal is to develop nanocarrier for targeted delivery of corticosteroids and immunosuppressants.
Thursday, April 14, 2011
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
How Cholesterol Leads to Clogged Arteries
A new study shows that when immune cells called neutrophils are exposed to cholesterol crystals, they release large extracellular web-like structures that trigger the production of inflammatory molecules linked to artherosclerosis.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Ultrafast DNA Diagnostics
New technology developed by UC Berkeley bioengineers promises to make a workhorse lab tool cheaper, more portable and many times faster by accelerating the heating and cooling of genetic samples with the switch of a light.
Researchers Discover New Type of Mycovirus
Virus infects the fungus Aspergillus fumigatus, which can cause the human disease aspergillosis.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!